The latest news from academia, regulators
research labs and other things of interest
Posted: Jun 06, 2017
Dual-action cancer nanomedicine therapy
(Nanowerk News) A French-Australian research team has fabricated antibody-coated porous silicon nanoparticles that can actively target cells through binding to specific cell-surface receptors. They demonstrated that these nanoparticles can bind to and selectively deliver multiple therapeutics to human B cells in vitro.
By co-loading a chemotherapy drug with gold nanoclusters, the system took advantage of combined chemotherapy and hyperthermia therapy and provided synergistic effects in eradicating targeted cells.
In particular, as the team points out, they have highlighted the ability of gold nanoclusters to affect cells by an externally applied µW field, boosting the cytotoxicity of the co-loaded anticancer drug campthotecin.
Porous silicon nanoparticles (pSiNPs) are biodegradable, suitable for conjugation with targeting moieties, and excellent carriers of chemotherapy drugs. In this work, the scientists utilized these unique properties of porous silicon nanoparticles and loaded them with two different therapeutics, while immobilizing cell-specific antibodies to ensure active targeting.